肠道屏障愈合在预测炎症性肠病主要不良结局方面优于内镜缓解和组织学缓解:前瞻性ERIca试验
该前瞻性研究纳入181例临床缓解期炎症性肠病患者,采用共聚焦内镜评估肠道屏障功能,比较屏障愈合与内镜缓解、组织学缓解对主要不良结局的预测价值,发现屏障愈合在克罗恩病和溃疡性结肠炎中预测性能均最优,作者认为屏障功能分析或可作为未来临床试验的治疗目标。
要点
- 共聚焦内镜评估的屏障愈合对克罗恩病和溃疡性结肠炎主要不良结局的预测均优于内镜缓解和组织学缓解。
- 组织学缓解仅预测溃疡性结肠炎的无主要不良结局生存,对克罗恩病无预测作用。
- 内镜缓解患者无主要不良结局生存概率显著高于内镜活动期患者。
核心结论
- 屏障愈合与临床缓解期炎症性肠病患者疾病进展风险降低相关,预测性能优于内镜缓解和组织学缓解。
- 作者认为屏障功能分析或可作为未来临床试验的治疗目标。
研究设计与样本
- 前瞻性研究,基线时对临床缓解期炎症性肠病患者行回结肠镜检查,采用共聚焦内镜评估肠道屏障功能,并按既定评分评估内镜和组织学疾病活动度及屏障愈合。
- 最终分析纳入181例患者,其中克罗恩病100例,溃疡性结肠炎81例。
- 随访期间密切监测临床疾病活动度和主要不良结局的发生。
- 临床试验注册号NCT05157750。
主要发现
- 克罗恩病平均随访35个月、溃疡性结肠炎平均随访25个月期间,73%的克罗恩病患者和69%的溃疡性结肠炎患者经历至少1次主要不良结局。
- 内镜缓解的炎症性肠病患者无主要不良结局生存概率显著高于内镜活动期患者。
- 组织学缓解可预测溃疡性结肠炎患者的无主要不良结局生存,但不能预测克罗恩病患者的无主要不良结局生存。
- 在溃疡性结肠炎和克罗恩病中,共聚焦内镜评估的屏障愈合对无主要不良结局生存的预测均优于内镜缓解和组织学缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic and histologic remission have emerged as key therapeutic goals in the management of inflammatory bowel diseases (IBD) that are associated with favorable long-term disease outcomes. Here, we prospectively compared the predictive value of barrier healing with endoscopic and histologic remission for predicting long-term disease behavior in a large cohort of patients with IBD in clinical remission. METHODS: At baseline, patients with IBD in clinical remission underwent ileocolonoscopy with assessment of intestinal barrier function by confocal endomicroscopy. Endoscopic and histologic disease activity, as well as barrier healing, was prospectively assessed along established scores. During subsequent follow-up, patients were closely monitored for clinical disease activity and the occurrence of major adverse outcomes (MAOs): disease flares, IBD-related hospitalization or surgery, and initiation or dose escalation of systemic steroids, immunosuppressants, small molecules, or biological therapy. RESULTS: The final analysis included 181 patients, 100 with Crohn's disease [CD] and 81 with ulcerative colitis (UC). During a mean follow-up of 35 (CD) and 25 (UC) months, 73% of patients with CD and 69% of patients with UC experienced at least 1 MAO. The probability of MAO-free survival was significantly higher in patients with IBD with endoscopic remission compared with endoscopically active disease. In addition, histologic remission predicted MAO-free survival in patients with UC but not CD. Barrier healing on endomicroscopy was superior to endoscopic and histologic remission for predicting MAO-free survival in both UC and CD. CONCLUSIONS: Barrier healing is associated with decreased risk of disease progression in patients with clinically remittent IBD, with superior predictive performance compared with endoscopic and histologic remission. Analysis of barrier function might be considered as a future treatment target in clinical trials. CLINICALTRIALS: gov number, NCT05157750.
引用
- Rath T, Atreya R, Bodenschatz J, et al. Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial. Gastroenterology. 2022. PMID: 36279923. doi:10.1053/j.gastro.2022.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。